Skip to Main Content
dr-sabine-mueller-md-48051-1440x784-2x
dr-sabine-mueller-md-48051-320x320-2x

Sabine Mueller

MD PhD MAS

Pediatric neurologist
Pediatric neuro-oncologist

Dr. Sabine Mueller is a pediatric neuro-oncologist who specializes in caring for children with brain tumors and related genetic syndromes. Before completing medical school, she worked as a scientist, director of genomics and project leader for a brain tumor program at AGY Therapeutics, a biotechnology company in South San Francisco.

In her research, Mueller studies treatments for children with brain tumors, looking especially at improving long-term cognitive outcomes.

Mueller earned her medical degree at the Universität Hamburg Faculty of Medicine and earned a doctorate in biochemistry and molecular biology in collaboration with AGY. After a residency in pediatrics at Massachusetts General Hospital, she completed a fellowship in pediatric oncology at UCSF.

  • Education

    Universität Hamburg School of Medicine, MD, 2005

  • Residencies

    Massachusetts General Hospital, Pediatrics, 2006

  • Fellowships

    UCSF, Pediatric Neurology, 2009

    UCSF, Neuro-Oncology, 2010

"You become a friend. You become part of their family…. That close relationship is what's so special about our field."

Where I see patients (3)

    Decorative Caduceus

    Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients Wit...

    MTD is defined as the dose at which fewer than one-third of participants experience a dose limiting toxicity (DLT) for all participants who received at least one study intervention.

    Recruiting

    More about this study
    Decorative Caduceus

    BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Glioma...

    Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.

    Recruiting

    More about this study
    Decorative Caduceus

    Combination Therapy for the Treatment of Diffuse Midline Gliomas

    Percentage of participants alive and free from progression at 6 months after the initiation of the combination of the backbone (i.e., ONC201) with a novel agent given in the maintenance phase of therapy. The primary analysis for P...

    Recruiting

    More about this study
    Decorative Caduceus

    Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Gli...

    Will assess the percentage change in cell cycle-related genetic signature post administration of neoadjuvant treatments when compared to archived recurrent pediatric HGG group. The number of participants with high cell cycle gene ...

    Recruiting

    More about this study
    Decorative Caduceus

    Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

    Progression-free survival is defined as the time of documented response until disease progression as defined by Response assessment in neuro-oncology criteria (RANO) criteria. PFS will be reported by overall group at 12 months.

    Recruiting

    More about this study
    Decorative Caduceus

    Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

    Adverse events and clinically significant laboratory abnormalities (meeting grade 3, 4, or 5 criteria according to NCI CTCAE) will be summarized by maximum intensity and relationship to study drug(s). Grade 1 and 2 adverse events ...

    Recruiting

    More about this study
    Decorative Caduceus

    ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent...

    A DLT is defined as a treatment-related adverse event (AE) or abnormal laboratory value that occurs in the first cycle of treatment (Cycle 1 for Arm A and D; Cycle 0 for Arm B and C), meets criteria for DLT as outlined below and i...

    Recruiting

    More about this study
    Decorative Caduceus

    Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gl...

    We will employ the Bayesian optimal interval (BOIN) design to find the MTD for both continuous and intermittent dosing schedules. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more fl...

    Recruiting

    More about this study
    Decorative Caduceus

    Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma

    Time to tissue collection will be used to determine the feasibility of using the results of real-time in vitro drug screening, WES and RNAseq of participant-derived specimens to guide treatment recommendations by a specialized tum...

    Recruiting

    More about this study
    Decorative Caduceus

    A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients ...

    Safety and tolerability as assessed by the frequency and severity of dose-limiting toxicities (DLTs), AEs, laboratory and ECG tests, vital signs, weight, physical and neurological exams.

    Recruiting

    More about this study
    See all clinical trials

    Stress-free visits

    Accommodations. Admissions. Procedure prep. Get the info you need for smoother hospital stays.

    Prepare for your child's stay

    Share